î
îŒ
î
LENZ Therapeutics Inc
LENZ16.890USD
-0.730-4.14%
çµå€Â 12/23, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
482.86Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± LENZ Therapeutics Inc äŒæ¥å
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Companyâs lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãLENZ
äŒç€ŸåLENZ Therapeutics Inc
äžå Žæ¥Jun 25, 2021
æé«çµå¶è²¬ä»»è
ãCEOãSchimmelpennink (Evert)
åŸæ¥å¡æ°42
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jun 25
æ¬ç€Ÿæåšå°- -
éœåž- -
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœ- -
éµäŸ¿çªå·- -
é»è©±çªå·- -
ãŠã§ããµã€ã- -
äŒæ¥ã³ãŒãLENZ
äžå Žæ¥Jun 25, 2021
æé«çµå¶è²¬ä»»è
ãCEOãSchimmelpennink (Evert)
LENZ Therapeutics Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Mon, Nov 17
æŽæ°æå»: Mon, Nov 17
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
ä»ã®
56.13%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
ä»ã®
56.13%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Venture Capital
34.49%
Investment Advisor
26.63%
Hedge Fund
23.81%
Investment Advisor/Hedge Fund
15.67%
Individual Investor
2.52%
Research Firm
2.01%
Pension Fund
0.17%
Bank and Trust
0.13%
Insurance Company
0.02%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Sun, Oct 5
æŽæ°æå»: Sun, Oct 5
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
267
30.95M
100.67%
+981.38K
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
UBS Financial Services, Inc.
881.48K
3.09%
+214.32K
+32.12%
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Tang Capital Management, LLC
897.62K
3.15%
+130.68K
+17.04%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
State Street SPDR S&P Pharmaceuticals ETF
1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
0.27%
iShares U.S. Pharmaceuticals ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.06%
詳现ãèŠã
State Street SPDR S&P Pharmaceuticals ETF
æ¯ç1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
æ¯ç1.04%
Virtus LifeSci Biotech Clinical Trials ETF
æ¯ç0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
æ¯ç0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
æ¯ç0.27%
iShares U.S. Pharmaceuticals ETF
æ¯ç0.22%
ProShares Ultra Nasdaq Biotechnology
æ¯ç0.11%
iShares Micro-Cap ETF
æ¯ç0.09%
Invesco Nasdaq Biotechnology ETF
æ¯ç0.08%
iShares Biotechnology ETF
æ¯ç0.06%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
Mar 19, 2024
Merger
7â1
Mar 19, 2024
Merger
7â1
Mar 19, 2024
Merger
7â1
Mar 19, 2024
Merger
7â1
æ¥ä»
çš®é¡
æ¯ç
Mar 19, 2024
Merger
7â1
Mar 19, 2024
Merger
7â1
Mar 19, 2024
Merger
7â1
Mar 19, 2024
Merger
7â1
ãããã質å
LENZ Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îLENZ Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
RA Capital Management, LPã¯4.18Mæ ªãä¿æããŠãããããã¯å šäœã®14.65%ã«çžåœããŸãã
Alpha Wave Global, LPã¯3.61Mæ ªãä¿æããŠãããããã¯å šäœã®12.66%ã«çžåœããŸãã
Versant Venturesã¯2.88Mæ ªãä¿æããŠãããããã¯å šäœã®10.10%ã«çžåœããŸãã
Ridgeback Capital Management, L.P.ã¯1.95Mæ ªãä¿æããŠãããããã¯å šäœã®6.84%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯1.29Mæ ªãä¿æããŠãããããã¯å šäœã®4.52%ã«çžåœããŸãã
RA Capital Management, LPã¯4.18Mæ ªãä¿æããŠãããããã¯å šäœã®14.65%ã«çžåœããŸãã
Alpha Wave Global, LPã¯3.61Mæ ªãä¿æããŠãããããã¯å šäœã®12.66%ã«çžåœããŸãã
Versant Venturesã¯2.88Mæ ªãä¿æããŠãããããã¯å šäœã®10.10%ã«çžåœããŸãã
Ridgeback Capital Management, L.P.ã¯1.95Mæ ªãä¿æããŠãããããã¯å šäœã®6.84%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯1.29Mæ ªãä¿æããŠãããããã¯å šäœã®4.52%ã«çžåœããŸãã
LENZ Therapeutics Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îLENZ Therapeutics Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
RA Capital Management, LP
Alpha Wave Global, LP
Versant Ventures
RA Capital Management, LP
Alpha Wave Global, LP
Versant Ventures
LENZ Therapeutics IncïŒLENZïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãLENZ Therapeutics Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯267瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ30.95Mã§ãå
šäœã®100.67%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-3.78%å¢å ããŠããŸãã
LENZ Therapeutics Incã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãLENZ Therapeutics Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
